|
|
- 2017
尿路上皮癌BRCA1基因与蛋白表达的相关性
|
Abstract:
| [1] | Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. |
| [2] | 韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95. |
| [3] | Jhanwar-Uniyal M. BRCA1 in cancer cell, cycle and genomic stability[J]. Front Biosci, 2003, 8(9): 1107-1117. |
| [4] | Seery LT, Knowlden JM, Gee JM, et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers[J]. Int J Cancer, 1999, 84(3): 258-262. |
| [5] | Joerger M, deJong D, Burylo A, et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy[J]. Lung Cancer, 2011, 74(2): 310-317. |
| [6] | Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and /or docetaxe[J]. BMC Cancer, 2008, 8(1): 197. |
| [7] | Raj GV, Karavadia S, Schlomer B, et al. Conmporary use of perioperative cisplatin-based chemotherapy in patients with muscle invasive bladder cancer[J] , Cancer, 2011, 117(2): 276-282. |
| [8] | Wang B, Matsuoka S, Ballif BA, et al. Abmxas and RAP80 form a BRCAI protein complex required for the DNA damage response[J]. Science, 2007, 316(5828): 1194-1198. |
| [9] | Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers[J]. Nat Rev Cancer, 2004, 4(10): 814-819. |
| [10] | Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression[J]. PLoS One, 2009, 4(5): 5133. |
| [11] | Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors[J]. J Natl Cancer Inst, 2000, 92(7): 564-569. |
| [12] | Taron M, Rosell R, Felip E, et al. BRCAl mRNA expression levels as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genet, 2004, 13(20): 2443-2449. |
| [13] | Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway[J]. Oncogene, 2001, 20(45): 6597-6606. |
| [14] | Gallagher DJ,Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinumsensitivity[J]. Ann Oncol, 2011, 22(5): 1127-1132. |
| [15] | Neveling K, Kalb R, Florl AR, et al. Disruption of the FA/BRCA pathway in bladder cancer[J]. Cytogenet Genome Res, 2007, 118(2-4): 166-176. |
| [16] | Font A, Taron M, Gago JL, et al. BRCAl mRNA expression and outcome to neoadjuvant cisplatin-based chemothorapy in baadder cancer[J]. Ann Oncol, 2011, 22(1): 139-144. |
| [17] | 那彦群, 孙光. 中国泌尿外科疾病诊断治疗指南[M]. 北京: 人民卫生出版社, 2011: 32. |
| [18] | Cheung G, Sahai A, Billia M, et al. Recent advances in the diagnosis and treatment of bladder cancer[J]. BMC Med, 2013, 11: 13. |
| [19] | Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer[J]. Lancet Oncol, 2003, 4(8): 489-497. |
| [20] | 徐光辉, 李玉, 叶胜龙, 等. 结直肠癌组织中ERCC1和BRCA1的表达及其与铂类化疗疗效的相关性[J]. 复旦学报(医学版), 2011, 38(4): 352-323. XU Guanghui, LI Yu, YE Shenglong, et al. ERCC1 and BRCA1 expressions in the tissues of colorectal cancer and its relationship with clinical significance of platinum-based chemotherapy[J]. Fudan University Journal of Medical Sciences, 2011, 38(4): 352-323. |
| [21] | Fedeli U, Fedewa SA, Ward EM, et al. Treatment of muscle invasive bladder cancer evidence from the National Cancer Database, 2003 to 2007[J]. J Urol, 2011, 185(1): 72-78. |
| [22] | Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis[J]. Cancer Res, 2003, 63(19): 6221-6228. |
| [23] | Lotti LV, Ottini L, D'Amico C, et al. Subcellular localization of the BRCA1 gene product in mitotic cells[J]. Genes Chromosomes Cancer, 2002, 35(3): 193-203. |
| [24] | 周利群, 李学松, 熊耕砚. 中国人群尿路上皮癌新进展[J]. 北京大学学报(医学版), 2014, 46(4): 504-506. |
| [25] | Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier[J]. Cancer Res, 1998, 58(15): 3237-3242. |
| [26] | 谷海燕, 项锋钢, 信芳杰, 等. NSCLC含铂新辅助化疗后ERCC1和BRCA1表达及与疗效关系[J].齐鲁医学杂志, 2012, 27(2): 98-100. GU Haiyan, XIANG Fenggang, XIN Fangjie, et al. Expressionsof erccland brcaland their relationship with curative effect in non-small cell lung cancer after platinum-based neoadjuvant chemo therapy[J]. Medical Journal of Qilu, 2012, 27(2): 98-100. |
| [27] | Kennedy RD, Quinn JE, Johnston PG, et al. BRCA1: mechanisms of inactivation and implications for management of patients[J]. Lancet, 2002, 360(9338): 1007-1014. |
| [28] | Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCAl function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo[J].Cancer Biol Ther, 2009, 8(7): 648-653. |
